The researchers found that Paxlovid reduced hospitalizations among people 65 and older by roughly 75% when given shortly after infection:
. For younger adults, in particular, that greatly reduces their risks of severe COVID-19 complications. The Centers for Disease Control and Prevention recently estimated that 95% of Americans 16 and older have acquired some level of immunity against the virus.
A spokesman for Pfizer declined to comment on the results, which were published in the New England Journal of Medicine.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Study: Pfizer COVID pill showed no benefit in younger adultsPfizer’s COVID-19 pill appears to provide little or no benefit for younger adults.
Leer más »
Study: Pfizer COVID pill showed no benefit in younger adultsPfizer's COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization and death for high-risk seniors, according to a large study published Wednesday.
Leer más »
Study: Pfizer COVID pill showed no benefit in younger adultsPfizer’s COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization and death for high-risk seniors, according to a large study published Wednesday.
Leer más »
Paxlovid, Pfizer's COVID pill, showed no measurable benefit in adults 40 to 65, study saysPfizer's COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization and death for high-risk seniors, according to a large study published Wednesday.
Leer más »
COVID Antivirals Like Paxlovid ‘Vastly Underused' During Pandemic, Study SaysDespite clinical trials showing that it could significantly reduce the risk of death in COVID patients, studies have shown that antivirals like Paxlovid are being “vastly underused” during the pandemic.
Leer más »